EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparative Cost-Effectiveness Analysis of Respiratory Syncytial Virus Vaccines for Older Adults in Hong Kong

Yingcheng Wang iD, Ginenus Fekadu iD, Joyce H S You iD

Vaccines · 17.10.2023 · 11 (10) · 1605

DOI: 10.3390/vaccines11101605 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 17.10.2023. Verfasst von Yingcheng Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese University of Hong Kong Direct Grant for Research, Direct Grant for Research (The Chinese University of Hong Kong).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Two respiratory syncytial virus (RSV) vaccines (AREXVY® and ABRYSVO®) were recently approved for older adults in the US. This study aimed to evaluate the cost-effectiveness of AREXVY® and ABRYSVO® from the Hong Kong public healthcare provider’s perspective. A two-year decision-analytical model was developed to examine the outcomes of a single RSV vaccination (AREXVY® or ABRYSVO®) compared to no vaccination. Primary outcomes included RSV-related health outcomes, direct medical costs, quality-adjusted life-year (QALY) loss, and incremental cost per QALY (ICER). RSV vaccines are not yet marketed in Hong Kong, base-case analysis, therefore, benchmarked US RSV vaccine prices at 4 levels (25%, 50%, 75%, 100%). AREXVY® and ABRYSVO® (versus no vaccination) gained 0.000568 QALY and 0.000647 QALY, respectively. ICERs of ABRYSVO® (26,209 USD/QALY) and AREXVY® (47,485 USD/QALY) were lower than the willingness-to-pay threshold (49,594 USD/QALY) at 25% US vaccine price. The RSV attack rate was a common influential factor at all vaccine price levels. The probabilities of AREXVY® and ABRYSVO® to be most cost-effective were 0.10% and 97.68%, respectively, at 25% US vaccine price. Single vaccination of ABRYSVO® or AREXVY® for older adults appears to gain QALYs over 2 years in Hong Kong. The cost-effectiveness of AREXVY® and ABRYSVO® is subject to vaccine price and RSV attack rate.

Schlagwörter

Stichwörter der Autor:innen

cost-effectiveness analysisolder adultsrespiratory infectionrespiratory syncytial virusvaccination

Autor:innen und Institutionen

  • School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.

ORCID-Profile: Yingcheng Wang, Ginenus Fekadu, Joyce H S You

Förderung

  • Chinese University of Hong Kong Direct Grant for Research
  • Direct Grant for Research (The Chinese University of Hong Kong)

Zitieren

APA

Wang, Y., Fekadu, G., & You, J. H. S. (2023). Comparative Cost-Effectiveness Analysis of Respiratory Syncytial Virus Vaccines for Older Adults in Hong Kong. Vaccines, 11(10), 1605. https://doi.org/10.3390/vaccines11101605

Vancouver

Wang Y, Fekadu G, You JHS. Comparative Cost-Effectiveness Analysis of Respiratory Syncytial Virus Vaccines for Older Adults in Hong Kong. Vaccines. 2023;11(10):1605. doi:10.3390/vaccines11101605

BibTeX
@article{Wang2023,
  author = {Wang, Yingcheng and Fekadu, Ginenus and You, Joyce H S},
  title = {Comparative Cost-Effectiveness Analysis of Respiratory Syncytial Virus Vaccines for Older Adults in Hong Kong},
  journal = {Vaccines},
  year = {2023},
  volume = {11},
  number = {10},
  pages = {1605},
  doi = {10.3390/vaccines11101605}
}
Kostenlos starten →